1-4 of 4
Atekelt Tadese
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Response-Adapted Treatment with Venetoclax, Obinutuzumab, and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-Cell Malignancies

Rahul Lakhotia, Christopher Melani, Stefania Pittaluga, James D Phelan, Amynah Pradhan, Atekelt Tadese, Candis Morrison, Sarah Evans, Seth M. Steinberg, William Figg, Elaine S Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski
Journal: Blood
Blood (2023) 142 (Supplement 1): 6172.
https://doi.org/10.1182/blood-2023-178766
Published: 2023
Journal Articles

Preliminary Analysis of an Ongoing Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma

Rahul Lakhotia, Christopher Melani, Jagan R. Muppidi, Stefania Pittaluga, James D Phelan, Colleen Ramsower, Lisa M. Rimsza, Ryan S Robertorye, George Wright, Mark Meerson, Ekaterina Postovalova, Alexander Bagaev, Nathan Fowler, Liza Lindenberg, Esther Mena, Ethan Bergvall, Amynah Pradhan, Atekelt Tadese, Candis Morrison, Sarah Evans, Sumaya Berg, Seth M. Steinberg, William Figg, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski
Journal: Blood
Blood (2023) 142 (Supplement 1): 1676.
https://doi.org/10.1182/blood-2023-185038
Published: 2023
Journal Articles

Nivolumab in Lymphomatoid Granulomatosis (LYG) and Other Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders (LPDs) and Non-Hodgkin Lymphomas (NHLs) with Systemic and/or CNS Involvement: Preliminary Analysis of Efficacy and Safety from an Ongoing Phase II Study

Disha Dalela, Rahul Lakhotia, Stefania Pittaluga, Jagan R. Muppidi, James D Phelan, Amynah Pradhan, Sarah Evans, Candis Morrison, Atekelt Tadese, Seth M. Steinberg, Jeffrey Cohen, Elaine S. Jaffe, Wyndham H Wilson, Mark Roschewski, Christopher Melani
Journal: Blood
Blood (2023) 142 (Supplement 1): 4408.
https://doi.org/10.1182/blood-2023-180217
Published: 2023
Journal Articles

Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D Phelan, Da Wei Huang, George Wright, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances A Tosto, Yandan Yang, Weihong Xu, Theresa Davies-Hill, Svetlana Pack, Cody J Peer, Oluwatobi Arisa, Esther Mena, Maria L. Lindenberg, Ethan Bergvall, Craig A. Portell, Rafic J Farah, Seung Tae Lee, Amynah Pradhan, Candis Morrison, Atekelt Tadese, Anna M Juanitez, Crystal Lu, Allison P. Jacob, Heidi Simmons, William D Figg, Seth M. Steinberg, Elaine S Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H Wilson
Journal: Blood
Blood (2023) 142 (Supplement 1): 434.
https://doi.org/10.1182/blood-2023-180173
Published: 2023